Physician profile
Jon Trister
NPI 1639131352
$3,368.69
in general payments reported to CMS, 2019-2025
21 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.68 · 2021: $21.64 · 2022: $23.77 · 2023: $46.23 · 2024: $1,045 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.26 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $504.30 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $373.98 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $293.81 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $241.89 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $229.90 | 2024-2025 | Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $165.95 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $154.23 | 2025 | Zoryve |
| Amgen INC. | $151.52 | 2024-2025 | Repatha, Repatha, Otezla |
| Ardelyx, INC. | $145.34 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.71 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.16 | 2025 | Xifaxan |
| Allergan, INC. | $71.68 | 2019 | |
| Abbott Laboratories | $67.44 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $62.51 | 2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $61.92 | 2024-2025 | |
| Astellas Pharma US INC | $47.43 | 2024 | Veozah |
| Scpharmaceuticals INC. | $24.28 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.77 | 2022 | |
| Glaxosmithkline, LLC. | $18.94 | 2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $15.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Trister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.